Canadian dermatology today.
Beyond Weight Loss: Practical Considerations for use of Glucagon like Peptide-1 (GLP-1) and Incretin Therapy in Inflammatory Skin Disease
By Jeffery Shi.
Abstract
The use of glucagon-like peptide-1 (GLP-1) based therapies has emerged as a topic in dermatology due to the strong bi directional association between obesity and immune-mediated inflammatory skin disease. The expanding benefits toward cardiometabolic health with GLP-1 and other incretin therapies supports the existence of a “skin-heart-metabolic” axis, prompting a shift from purely skin-directed therapies to holistic and systemic patient management. Dermatologists should be aware of the mechanisms, clinical evidence, safety profiles, and practical prescribing considerations of existing and novel drugs.
Keywords
- Diabetes Treatment and Management
- glucagon-like peptide-1
- GLP-1 receptor agonists
- incretin-based therapy
- inflammatory skin diseases
- obesity
- cardiometabolic health
- drug safety
- weight loss
- Open access
Source
Published in Canadian dermatology today.. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
